Five Prime Therapeutics to Present at 26th Annual Roth Conference

        Print
| Source: Five Prime Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif., March 5, 2014 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Aron Knickerbocker, Chief Business Officer of Five Prime, will present at the 26th Annual Roth Conference on Tuesday, March 11 at 5:30 p.m. Pacific Time. The conference will take place at the Ritz-Carlton Hotel in Laguna Niguel, California.

The live webcast will be accessible at http://investor.fiveprime.com/events.cfm or as a direct feed from http://wsw.com/webcast/roth28/FPRX. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.

About Five Prime

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases. Five Prime has leveraged its comprehensive library of human extracellular proteins and its proprietary high-throughput screening technologies to produce new targets for protein therapeutics to be advanced by partners or in the company's internal pipeline. Five Prime currently has two therapeutics in clinical testing. FP-1039 (GSK3052230) is a fibroblast growth factor (FGF) ligand trap being developed in collaboration with GlaxoSmithKline to treat multiple solid tumors. A global, multi-arm Phase 1b study of FP-1039 in combination with standard chemotherapy in FGFR1-amplified squamous non-small cell lung cancer (NSCLC) and mesothelioma is underway. A second drug candidate is FPA008, which inhibits colony stimulating factor-1 receptor (CSF1R) activation and is being developed to treat rheumatoid arthritis, is in a Phase 1 trial currently enrolling. Five Prime is also conducting IND-enabling activities for FPA144, an antibody that blocks signaling through fibroblast growth factor receptor 2b (FGFR2b) and is glyco-engineered for enhanced antibody-dependent cytotoxicity.

Additional information can be found at the company's website: www.fiveprime.com.

COMPANY CONTACT:

Amy Kendall
Corporate Communications
415-365-5776